Published in Prog Neurobiol on March 21, 2012
Application and Revision of Montreal Cognitive Assessment in China's Military Retirees with Mild Cognitive Impairment. PLoS One (2016) 1.39
Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des (2013) 1.22
Precortical Phase of Alzheimer's Disease (AD)-Related Tau Cytoskeletal Pathology. Brain Pathol (2015) 0.86
Selective alterations of neurons and circuits related to early memory loss in Alzheimer's disease. Front Neuroanat (2014) 0.85
Neurofibrillary tangles and the deposition of a beta amyloid peptide with a novel N-terminal epitope in the brains of wild Tsushima leopard cats. PLoS One (2012) 0.84
Amylin at the interface between metabolic and neurodegenerative disorders. Front Neurosci (2015) 0.81
Acetyl-CoA the key factor for survival or death of cholinergic neurons in course of neurodegenerative diseases. Neurochem Res (2013) 0.79
"Is dopamine involved in Alzheimer's disease?". Front Aging Neurosci (2014) 0.79
Reduced striatal ecto-nucleotidase activity in schizophrenia patients supports the "adenosine hypothesis". Purinergic Signal (2013) 0.78
Olfactory Receptors in Non-Chemosensory Organs: The Nervous System in Health and Disease. Front Aging Neurosci (2016) 0.78
Magnesium protects cognitive functions and synaptic plasticity in streptozotocin-induced sporadic Alzheimer's model. PLoS One (2014) 0.78
Selection of controls in the study of human neurodegenerative diseases in old age. J Neural Transm (Vienna) (2014) 0.77
Hippocampal volume and hippocampal angle (a more practical marker) in mild cognitive impairment: A case-control magnetic resonance imaging study. Adv Biomed Res (2015) 0.77
Mechanisms of Alzheimer's Disease Pathogenesis and Prevention: The Brain, Neural Pathology, N-methyl-D-aspartate Receptors, Tau Protein and Other Risk Factors. Clin Psychopharmacol Neurosci (2017) 0.75
CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease. Front Neurosci (2016) 0.75